febuxostat / Generic mfg. - LARVOL DELTA

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience (ASH 2025) - "Background : Venetoclax (VEN)+obinutuzumab (VO) is an effective therapy for CLL/SLL requiring regularmonitoring for tumor lysis syndrome (TLS) during VEN ramp-up...Adult pts with CLL/SLL were eligible if they: (1) startedVO per-label outside of a clinical trial in 1L, or immediately after exposure in 1L to agents with differentmechanisms of action (i.e., BTKi, anti-CD20 only) of <30 days; (2) prior to VEN start, had either (i) lowphysician-determined tumor burden (TB) (i.e., all lymph nodes [LN] <5 cm and ALC <25 x 109/L), or (ii)medium physician-determined TB (i.e., any LN ≥5-<10 cm or ALC ≥25 x 109/L) with creatinine clearance≥80 mL/min; (3) had no strong CYP3A inhibitors or prophylactic rasburicase from 3 days prior to VENstart until end of VEN ramp-up; and (4) had VEN ramp-up in an outpatient setting.TB-related labs/imaging was assessed from 2 months prior to obinutuzumab initiation (i.e., index date)until VEN start...Prior to VEN ramp-up, all pts..."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Diabetes • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • IGH • TP53

Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients (clinicaltrials.gov) - P2 | N=60 | Completed | Sponsor: Mostafa Bahaa | Recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Dec 2025 | Trial primary completion date: Aug 2026 ➔ Dec 2025

Trial completion • Trial completion date • Trial primary completion date • Gout • Inflammatory Arthritis • Metabolic Disorders • Obesity • Rheumatology

A Multicenter, Randomized, Double-Blind, Placebo/Febuxostat-Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout and Hyperuricemia: Results from the 24-Week Extension Period of the Phase 2b Study (ACR Convergence 2026) - No abstract available

Clinical • P2/3 data • P2b data • Gout • Inflammatory Arthritis • Rheumatology

Efficacy and Safety of Ultra-Low Starting Dose Febuxostat Titration in Male Patients With Primary Gout. (PubMed, Int J Rheum Dis) - "Initiating febuxostat at a dose of 10 mg/day with gradual titration demonstrates a superior safety profile by effectively reducing early acute flares without compromising long-term urate control, which is particularly advantageous for high-risk cohorts, including obese patients."

Biomarker • Clinical • Journal • Gout • Hepatology • Immunology • Inflammatory Arthritis • Liver Failure • Obesity • Rheumatology

Efficacy and Safety of HR091506 Extended-Release Tablets Versus Febuxostat in Patients With Gout and Hyperuricemia: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase 3 Trial (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Gout • Inflammatory Arthritis • Rheumatology

Reevaluating Febuxostat's Cardiovascular Black Box Warning: Comparative Safety Versus Allopurinol in a Large U.S. Gout Cohort. (ACR Convergence 2026) - No abstract available

Clinical • Cardiovascular • Gout • Inflammatory Arthritis • Rheumatology

Differential associations of febuxostat and allopurinol with incident and worsening frailty risk in nephrology patients. (PubMed, Int J Med Sci) - "Among nephrology patients, UA-lowering therapy showed divergent associations with frailty probability: febuxostat use correlated with higher whereas allopurinol use correlated with lower incident frailty probability, with no effect on frailty progression. Choice of UA-lowering therapy may have implications for functional outcomes in this high-risk population."

Journal • Retrospective data • Chronic Kidney Disease • Gout • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology

Experience with early treatment using febuxostat in a patient with adenine phosphoribosyltransferase deficiency after pediatric kidney transplantation: a case report. (PubMed, CEN Case Rep) - "Kidney transplantation (KT) for adenine phosphoribosyltransferase (APRT) deficiency is performed using the xanthine dehydrogenase (XDH) inhibitor allopurinol to prevent the recurrence of dihydroxyadenine (DHA) nephropathy. Transplant renal biopsy at 4 months post-KT showed no recurrence of DHA nephropathy; graft function remained stable. This case demonstrated that pediatric patients with APRT deficiency undergoing KT could be successfully managed with febuxostat."

Journal • Acute Kidney Injury • Chronic Kidney Disease • Infectious Disease • Nephrology • Pediatrics • Transplantation • Urolithiasis

Tigulixostat (IBI128) vs Febuxostat in Gout (clinicaltrials.gov) - P3 | N=600 | Active, not recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Recruiting ➔ Active, not recruiting

Enrollment closed • Gout • Inflammatory Arthritis • Rheumatology

Cinnamaldehyde Attenuates Hyperuricemia-Associated Renal Injury by Modulating Urate Transporters and AIF1- and CMPK2/NLRP3-Related Inflammatory Signaling. (PubMed, Pharmaceuticals (Basel)) - "For the in vivo study, mice were divided into five groups (control, model, febuxostat, low-dose CA, and high-dose CA; n = 9 per group) and were treated by oral gavage... These findings suggest that CA alleviates hyperuricemia-associated renal injury by regulating renal urate transporters, attenuating AIF1- and CMPK2/NLRP3-related inflammatory signaling, accompanied by compositional shifts in selected gut microbial taxa that warrant further mechanistic investigation. The study provides experimental support for further evaluation of cinnamaldehyde as a multi-target candidate for hyperuricemia-related renal injury."

Journal • Chronic Kidney Disease • Gout • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology • ABCG2 • AIF1 • IL18 • IL1B • NLRP3 • SLC22A2

Virtual screening of Hops-derived Xanthine oxidase inhibitors (ACS-Fall 2026) - "Although commonly used clinical drugs such as allopurinol and febuxostat demonstrate established efficacy, they are associated with significant side effects, and therefore, the development of novel, potent, and low-toxicity natural XOD inhibitors is of great significance. Our research aims to screen for XOD inhibitors from hops using computer-aided virtual screening methods, integrating three-dimensional quantitative structure-activity relationship (3D-QSAR) pharmacophore screening and batch molecular docking. Finally, the screened compounds are validated for in vitro XOD inhibitory activity, and their inhibition kinetic types and molecular mechanisms of action are further investigated."

Diabetes • Gout • Inflammatory Arthritis • Metabolic Disorders

Time-varying cardiovascular risk of febuxostat versus allopurinol in gout: a one-stage meta-analysis. (PubMed, Rheumatology (Oxford)) - "The cardiovascular and mortality risk of febuxostat relative to allopurinol is time-dependent, showing a significant early reduction that attenuates over time. These findings advocate for a time-aware approach to clinical management and monitoring."

Journal • Retrospective data • Cardiovascular • Gout • Inflammatory Arthritis • Rheumatology

Controversies in Urate-Lowering Therapy for Gout: A Comprehensive Review. (PubMed, Gout Urate Cryst Depos Dis) - "In the following, we discuss several of these controversies and some of the most recent literature regarding potential future changes in recommended management of gout. We discuss options for prophylactic therapy and length, treating gout concomitantly with its most common comorbidities, hypertension, diabetes mellitus, and cardiovascular disease, potential debulking therapy for more severe gout, and optimal urate levels."

Journal • Cardiovascular • Diabetes • Gout • Hypertension • Immunology • Inflammatory Arthritis • Metabolic Disorders • Rheumatology

Safety profiles of two XOD and two URAT1 inhibitors in hyperuricemic patients: a real-world pharmacovigilance analysis based on the FAERS and JADER databases. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Allopurinol, febuxostat, dotinurad, and benzbromarone are commonly used clinically as uric acid-lowering drugs. This study compares ADR signaling differences between two XOD and two URAT1 inhibitors as well as high-risk signals, providing evidence for clinical monitoring of drug safety. However, large-scale prospective studies are still needed for future validation."

Adverse events • Journal • Real-world evidence • Acute Kidney Injury • Eosinophilia • Gout • Hepatology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology • Septic Shock

Green Sensitive Derivative Emission Spectrofluorimetry for the Estimation of Repaglinide and Febuxostat Simultaneously in Dosage Forms and Spiked Human Plasma. (PubMed, Luminescence) - "The validation was performed in accordance with ICH guidelines and the amplitude first derivative (1D) versus concentrations curves covered concentration ranges of 0.01-0.18 μg/mL for REP and 0.03-0.2 μg/mL for FEB. The suggested approach was effectively used to determine the two drugs in spiked human plasma samples in ranges 0.01-0.2 μg/mL for REP and 0.05-0.2 μg/mL for FEB. The proposed technique was effectively used to identify the (REP) and (FEB) in multiple pharmaceutical products."

Journal

The Dual Role of Uric Acid: Pathological Implications Across Chronic Diseases and Current Approaches to Hyperuricemia Management. (PubMed, Discoveries (Craiova)) - "Allopurinol and Febuxostat, xanthine oxidase inhibitors, are used as first-line pharmacological therapies for the treatment of hyperuricemia, whereas uricosurics and Interleukin-1 (IL-1) inhibitors are preferred in cases of refractory hyperuricemia. It also outlines the already established management options and new innovative therapies for managing this disease. Understanding this dichotomous role is essential for adopting a precise management approach that balances the protective and pathological effects of uric acid."

Journal • Review • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Genetic Disorders • Gout • Hematological Disorders • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Nephrology • Renal Disease • Rheumatology • Systemic Lupus Erythematosus • Tobacco Cessation

Cardiovascular Safety of Febuxostat vs. Allopurinol in Gout Patients with Cardiovascular Diseases: A Target Trial Emulation. (PubMed, Clin Pharmacol Ther) - "Sensitivity analyses confirmed robustness. Findings suggest cautious febuxostat use in CVD patients, guiding personalized prescribing based on racial and lifestyle factors."

Journal • Cardiovascular • Gout • Inflammatory Arthritis • Rheumatology

Febuxostat enhances the anti-tumor efficacy of 2-fluoroadenine and 5'-methylthioadenosine in MTAP-deleted cancer. (PubMed, Cancer Res Commun) - "Xenograft studies using MTAP- HT1080 and MiaPaCa-2 cell lines show that a 2FA/MTA/FX cocktail can cause tumor regression in vivo. These studies suggest that a combination of 2FA/MTA/FX may be useful in treating MTAP- cancer."

Journal • Oncology • MTAP

Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis. (PubMed, Drugs Real World Outcomes) - "It was found that 2 mg/day of Dotinurad was superior to 40 mg/day of febuxostat in achieving serum UA levels ≤ 360 μmol/L or ≤ 300 μmol/L after 4 weeks in Chinese patients with gout and exerted superior short-term urate-lowering effectiveness to febuxostat. Additionally, dotinurad is not associated with a risk of hepatic or renal injury in the short term, whereas febuxostat may increase SCR levels over the short course. The conclusions are only applicable to the clinical medication setting where febuxostat is initiated at a dose of 40 mg in Chinese patients with gout."

Journal • Real-world evidence • Gout • Inflammatory Arthritis • Liver Failure • Renal Disease • Rheumatology

Risk of Major Adverse Cardiovascular Events in Patients Treated with Febuxostat Compared to Allopurinol: A Systematic Review and Meta-Analysis. (PubMed, Curr Rheumatol Rev) - "This review showed no significant differences between the two therapies across major cardiovascular endpoints."

Adverse events • Clinical • Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Gout • Heart Failure • Inflammatory Arthritis • Myocardial Infarction • Rheumatology

The efficacy and safety of benzbromarone and febuxostat in combined-type hyperuricemia: a single-center study. (PubMed, Clin Rheumatol) - "Benzbromarone and febuxostat demonstrated different early serum urate target attainment rates at 4 weeks, with a numerically higher unadjusted rate observed in the benzbromarone group that was attenuated and no longer statistically significant after multivariable adjustment. Cumulative target achievement converged over time among patients with extended follow-up. These findings require confirmation in prospective studies with extended follow-up to evaluate long-term clinical outcomes. Key Points • Low-dose benzbromarone showed a numerically higher 4-week serum urate target attainment rate than febuxostat, although this difference was not statistically significant after adjustment for confounders. • Concomitant sodium bicarbonate use was associated with earlier serum urate target attainment, although this association may reflect both the potential contribution of urinary alkalinization and treatment-selection patterns in routine clinical practice. •..."

Journal

Uric acid and heart failure. (PubMed, J Cardiol) - "In an US cohort study comprising approximately 100,000 participants using Medicare data, less aggravation of heart failure was observed in patients who were administered febuxostat compared to allopurinol. In this review, we discuss clinical trials on hyperuricemia with heart failure and its treatment. Further large-scale, high-quality, prospective intervention studies on the efficacy of treating hyperuricemia as a complication of heart failure are required."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Gout • Heart Failure • Hypertension • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology

Structure-activity relationship studies of febuxostat derivatives identify potent anti-lung cancer agents that induce DNA damage and autophagy. (PubMed, Sci Rep) - "Molecular docking analysis suggested that 14h could effectively bind to the active site of PARP through hydrogen bonding and π-π interactions with key residues, potentially contributing to DNA damage accumulation. Collectively, these findings indicate that compound 14h exerts potent anticancer activity through DNA damage-mediated activation of apoptotic and autophagic pathways, highlighting febuxostat-triazole hybrids as promising candidates for lung cancer therapy."

IO biomarker • Journal • Lung Cancer • Oncology • Solid Tumor • ATG7 • BCL2 • CASP6 • CASP9 • CDKN1A • KEAP1

An uncommon encounter with tumor lysis syndrome in colorectal cancer. (PubMed, Ger Med Sci) - "Prompt treatment with intravenous fluids, rasburicase, and febuxostat led to rapid resolution of TLS. Despite recovery, the patient died two weeks later from complications of advanced metastatic disease. This case highlights the need for early TLS recognition in high-risk CRC patients."

Journal • Acute Kidney Injury • Colorectal Cancer • Endocrine Disorders • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Solid Tumor

Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients (clinicaltrials.gov) - P2 | N=46 | Recruiting | Sponsor: Tanta University

New P2 trial • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders